2017 Press Releases

Webcast ImageWebcast
The LEERINK Partners 6th Annual Global Healthcare Conference (Replay)
02/15/17 at 10:00 a.m. ET
The LEERINK Partners 6th Annual Global Healthcare Conference
Wednesday, February 15, 2017 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Intellia Therapeutics Conference Call to Address CRISPR/Cas9 U.S. Patent Interference Proceedings (Replay)
02/16/17 at 8:00 a.m. ET
Intellia Therapeutics Conference Call to Address CRISPR/Cas9 U.S. Patent Interference Proceedings
Thursday, February 16, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
Intellia Therapeutics to Hold Conference Call to Address Patent Interference ProceedingsCAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief executive officer and founder, Jose E. Rivera, executive vice president and general counsel, and Graeme Bell, chief financial officer. To participate on the day of the call, dial 844-882-7840 and use Conference ID#... Click to view full release
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells U.S. Patent... Click to view full release
Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare ConferenceCAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan Bermingham, Ph.D., will present at the Leerink Partners 6th Annual Global Healthcare Conference, Wednesday, February 15, 2017.      Details of the presentation are as follows: Date: Wednesday, February 15, 2017 Loc... Click to view full release
Intellia Therapeutics Joins Genomics England’s Industry ConsortiumCAMBRIDGE, Mass. and LONDON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium, as the first, dedicated genome editing company to participate in the 100,000 Genomes Project. The GENE Consortium, established in M... Click to view full release